SKIN Stock Forecast & Price Target

SkinHealth Systems is attractive because its recurring consumables base and 36,516-system installed base support a resilient, high-margin revenue model, with roughly 75% of revenue tied to repeat consumable demand. Management is addressing adoption barriers through a new U.S. rental program, while HydraScalp, SkinStylus’s nearly 50% y/y growth in 2Q, and a clinically validated booster launch expected in 4Q26 broaden growth catalysts beyond core devices. Even with 2Q26 revenue down 8% y/y to $72M, adjusted EBITDA reached $17M and gross margin expanded to 71.8%, underscoring strong execution, cost discipline, and the potential for profitability to outpace still-muted top-line growth.

SkinHealth Systems is facing a weak fundamental setup because capital spending by providers remains cautious, driving Delivery Systems revenue down 18% y/y and leaving installed-base growth thin, with 770 placements producing only 97 net additions. Management also lowered FY26 revenue guidance to $280 million-$295 million while still expecting $35 million-$45 million of adj. EBITDA, highlighting limited visibility into a durable return to growth as consumables utilization stays pressured. Although cash of about $206 million exceeds the $91 million market cap and can cover the October 2026 convert, the November 2028 convertible maturity, ongoing litigation, regulatory risk, and weak 3Q26 guidance reinforce the balance-sheet and execution overhang.